Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
Key Highlights
- ➤ERNA-101 showed no treatment-related adverse findings across all doses in 50-day GLP toxicology study
- ➤No teratoma formation observed through six-month tumorigenicity in-life phase
- ➤No significant ERNA-101 signal detected in tumor-free animals or non-tumor tissues
- ➤Core IND-enabling safety studies complete; GMP manufacturing underway
- ➤Ernexa (ERNA) remains on track for planned Q4 2026 IND submission
Expert Statements
Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics
“We believe these results represent one of the most important milestones in Ernexa’s history because the ERNA-101 story is now coming together across efficacy, safety and tumor-targeted delivery”
Robert H. Pierce, M.D., Chief Scientific Officer of Ernexa Therapeutics
“From a scientific perspective, these findings provide important support for the fundamental design of ERNA-101”
Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics
“In straightforward terms, these results support what we designed ERNA-101 to do: find the tumor, deliver powerful immune-enhancing cytokines where they are intended to work and limit unnecessary exposure elsewhere in the body.”
Robert H. Pierce, M.D., Chief Scientific Officer of Ernexa Therapeutics
“A cytokine-armed cell therapy needs to be evaluated where its biology is active, in the presence of tumor and an intact immune system”
Robert H. Pierce, M.D., Chief Scientific Officer of Ernexa Therapeutics
“Biodistribution goes directly to the heart of the ERNA-101 thesis”
Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics
“We believe the significance is in the totality of the data”
Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics
“There is a point in the development of every potentially important new therapy when the question begins to change”
Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics
“Our objective now is clear: execute the IND submission, advance ERNA-101 into the clinic and begin determining whether the promise we have observed in preclinical models can translate into meaningful benefit for patients.”
Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed no evidence of acute cytokine release
No teratoma formation observed in ERNA-101-treated animals through the six-month tumorigenicity in-life phase, addressing a fundamental safety consideration for an iPSC-derived cell therapy
Get started
Create a free account to read the full story.